Notice: This lecture is a research seminar for credit.
September 27th, Tursday, 2018 1:30-2:30 p.m.
cancer is one of the most common cancers in China. Targeted therapies for
breast cancer was among the leading cancer strategy for disease diagnosis and
treatment that considers individual variability in genes, environment, and
lifestyle. Historically, breast cancer has been treated according to biomarkers
such as estrogen receptor and HER2 status. Treatment based on these markers
have generated the world-renowned milestones for targeted therapies. More and
more novel targets including both proteins and RNAs have been investigated
extensively, and some of them are on the way to be clinically available to
Tao Zhu became the Professor of University of
Science and Technology of China (USTC) and Principal Investigator at the Hefei
National Laboratory for Physical Sciences at Microscale under the scheme of
“Hundred-Talent” of Chinese Academy of Sciences since 2007. Emphasis in his
laboratory has focused on the
development of cancer secreted growth factors and ncRNAs as the
potential targets of novel cancer therapeutics. Dr. Zhu is co-author of over 90
peer-reviewed publications. His latest focus has produced more than 40
correspondence author work in Cell
PNAS, Cancer Res
as well as a few intellectual properties of potential enormous utility and
value. His work received more than 4000 citations and h-index=40. He
is an editorial board member of a number of international journals and 7
national or international granting agencies. He also served as consultant for a
few of international pharmaceutical companies, focused on development of
therapeutics to novel cancer target molecules.
Professors and students of TBSI are welcome to attend. The lecture is also open to the public. For off-campus personnel, please scan the QR code and and fill in your information (name, company, contact number, ID number). The language of the lecture is English.